— However, 24 weeks of the GLP-1 had no effect on eGFR
by Kristen Monaco, Senior Staff Writer, MedPage Today
October 29, 2024
SAN DIEGO– Semaglutide (Wegovy) decreased albuminuria in clients with obese or weight problems and persistent kidney illness (CKD) however without type 2 diabetes, a randomized trial revealed.
Amongst 101 clients, those who got 2.4-mg semaglutide for 24 weeks had a 52.1% (95% CI -65.5 to -33.4, P<0.0001) decrease in urine albumin-to-creatinine ratio (UACR) compared to those who got placebo, reported Hiddo J.L. Heerspink, PhD, of University Medical Center Groningen in the Netherlands, at the American Society of Nephrology Kidney Week conference.
“The albuminuria level step-wise reduced at each dosage titration action and reached the optimal result after 24 weeks,” he stated. “This result was sustained throughout the 4-week washout duration.”
The findings, which were likewise released in Nature Medicinecontribute to a growing body of proof showing semaglutide’s kidney advantages, though previous research studies have actually concentrated on clients with type 2 diabetes.
The stage III FLOW trial, which registered clients with type 2 diabetes and CKD, reported a 24% threat decrease in a composite kidney result with 1-mg semaglutide (Ozempic). Furthermore, the STEP-2 trial in type 2 diabetes and weight problems reported a 28% drop in albuminuria compared to placebo.
In the present trial, called SMART, the detectives randomized 51 clients to semaglutide and 50 to placebo. Typical age was 56, 40% were ladies, and 91% were white. The mean approximated glomerular purification rate (eGFR) was 65 mL/min/1.73 m2standard body mass index (BMI) was 36.2, and mean UACR was 251 mg/g.
The decrease in albuminuria with semaglutide corresponded throughout many subgroups, consisting of when stratified by standard HbA1c (<<5.6% vs ≥ 5.6%), standard BMI (≤ 35 vs>> 35), standard UACR (<<300 mg/g vs ≥ 300 mg/g), and standard eGFR (<<60 vs ≥ 60 mL/min/1.73 m2.
Of note, the decrease in albuminuria just reached significance in those not taking an SGLT2 inhibitor at standard and those with a CKD etiology of ischemic/hypertensive nephrology or other/unknown cases. Clients with persistent glomerulonephritis